Pediatric Neuroblastoma Treatment Market

Pediatric Neuroblastoma Treatment Market (Therapy Type - Immunotherapy, Chemotherapy; Distribution Channel - Hospital Pharmacies, Retail Pharmacies amd Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global Pediatric Neuroblastoma Treatment Market: An Overview

By the end of the forecast period of 2018 to 2026, the global pediatric neuroblastoma treatment will witness increase in market worth to USD 1.3 billion. The market would grow at a compound annual growth rate 8.9% over this period. This growth will manifest itself in the market in a number of ways including generation of a marked number of profitable opportunities. A large number of prominent factors of growth are marking the global pediatric neuroblastoma treatment market and are responsible for this growth.

Increasing awareness and efforts directed by governmesnts across the globe is set to improve outcomes is leading to notable growth in the market. It is an outcome of growing number of cases of pediatric neuroblastoma.

pediatric neuroblastoma treatment market

Thus, one notes intensive research and development going on across nations. This is paving way for better and more effective treatments. It will therefore help the market grow at a considerable pace over the forecast period. Advancement in technology also holds key place here as it is crucial in determining growth for the players as well overall market landscape.

Improving healthcare infrastructure, particularly in the developing regions of the world, will lead to growth in pediatric neuroblastoma treatment market. A high incidence of this condition is also a notable factor of growth in the market.  Governments are also directed efforts in this direction.

These factors are also leading to increase in awareness regarding the condition and that is leading to growth in the market as demand for effective treatments take on an upward growth curve. The only restrain that is set to mark the landscape over the forecast period, restraining the market from reaching its full growth potential is high costs of such treatments – therapies and drugs. Research and development in the field is also an expensive endeavor in the market.

The market for pediatric neuroblastoma has a number of players operating its playfield. Some of the dominant names are United Therapeutics Corporation, APEIRON Biologics AG, Baxter, CELLECTAR BIOSCIENCES, INC, Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Bayer AG, MacroGenics, Inc., and Sartorius AG, among others.

A number of strategies are often deployed by these players in order to grow. Therefore, one often notes players entering in to new alliances such as strategic partnerships and collaborations as these help in combining resources such as man-power, know-how, and so on in order to ensure growth. Besides, these are also responsible for helping players get better market penetration.

Other notable strategies are development of drugs and therapies. It creates a very prominent place for research and development (R&D) activities in the overall growth strategy. Besides, technological development also holds key to future growth.

Chemotherapy Segment to Dominate Global Pediatric Neuroblastoma Treatment Market over the Forecast Period

The global pediatric neuroblastoma treatment market report is segmented on the basis of therapy type and distribution channel. The former is sub-segmented into immunotherapy and chemotherapy. Distribution channels include examination of hospitals, pharmacies, retail pharmacies, and drug stores.

In 2017, the chemotherapy segment under the therapy type category held the dominant share and the trend is anticipated to roll into the forecast period. Besides, analysts claim that it will also grow at a very high rate over the forecast period. One of the biggest factors of growth that push the segment up is the high efficacy of the segment. It is highly preferred b physicians around the world for managing symptoms and progression. Additionally, it is quite pertinent to note here that it is also used in combination with other therapies such as radiation therapy.

Furthermore, on the basis of distribution channel, hospital pharmacies will top the growth charts owing to high preference and reliance on these for drug needs. In 2017 as well, this segment contributed massively to market growth. It is also important to make note of the fact here that there these enjoys high credibility in the market.

North America Expected to Dominate the Global Pediatric Neuroblastoma Treatment Market over the Forecast Period of 2018 to 2026

North America, Europe, Asia Pacific, and Rest of the World form various regional segments that report on pediatric Neuroblastoma treatment market, prepared by Transparency Market Research, covers. As per analysis, North America would account for a dominant share in the market over the forecast period and a number of factors would push it to that position.

For instance, high incidence of neuroblastoma is being noted in the North American region. This is contributing immensely to growth, which is projected for the region. Healthcare infrastructure here is robust and this is also owed to as far as rosy statistics are concerned. Besides, better reimbursement framework and growing awareness are also major growth propellers in the regional market.

It is also quite interesting to note here that the United States of America will be a notable contributor to growth in the market. Every year, 800 cases of neuroblastoma are reported in the country, states American Cancer Society.

On the other hand, it will be the Asia Pacific (APAC) region that displays a sturdy growth rate over the forecast period. Reasons that will be attributed to this growth are increase in public investment and improvement in healthcare infrastructure. Additionally, certain technological advancements, particularly those noted in India and China, are contributing massively to the steady trajectory. The region will also create opportunities – gainful and novel - for market players to tap into, in order to secure growth.

The global pediatric neuroblastoma treatment market has been segmented into:

Therapy Type

  • Immunotherapy
  • Chemotherapy
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Rest of Europe
  • Rest of the World

    1. Preface
              1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Pediatric Neuroblastoma Treatment Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Market Definition
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, 2016–2026
                4.4.1. Market Revenue Projections (US$ Mn)
         4.5. Porter’s Five Force Analysis

    5. Market Outlook
         5.1. Epidemiology Pediatric Neuroblastoma
         5.2. Pipeline Analysis
         5.3. Key Unmet Needs in the Pediatric Neuroblastoma Treatment Market
         5.4. Global Pediatric Neuroblastoma Treatment Market: Rate of Metastasis in Neuroblastoma
         5.5. Global Pediatric Neuroblastoma Treatment Market: Neuroblastoma Relapse/Refractory cases
         5.6. Rate of Utilization of MIBG-131

    6. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by Therapy Type
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Market Value Forecast, by Therapy Type, 2016–2026
                6.3.1. Immunotherapy
                6.3.2. Chemotherapy
                6.3.3. Others
         6.4. Market Attractiveness, by Therapy Type

    7. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by End-user
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Market Value Forecast, by Distribution Channel, 2016–2026
                7.3.1. Hospital Pharmacies
                7.3.2. Retail Pharmacies & Drug Stores
         7.4. Market Attractiveness, by Distribution Channel

    8. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by Region
         8.1. Key Findings
         8.2. Market Value Forecast, by Region
                8.2.1. North America
                8.2.2. Europe
                8.2.3. Rest of the World
         8.3. Market Attractiveness, by Region

    9. North America Pediatric Neuroblastoma Treatment Market Analysis and Forecast
         9.1. Introduction
                9.1.1. Key Findings
         9.2. Market Value Forecast, by Therapy Type, 2016–2026
                9.2.1. Immunotherapy
                9.2.2. Chemotherapy
                9.2.3. Others
         9.3. Market Value Forecast, by Distribution Channel, 2016–2026
                9.3.1. Hospital Pharmacies
                9.3.2. Retail Pharmacies & Drug Stores
         9.4. Market Value Forecast, by Country, 2016–2026
                9.4.1. U.S.
                9.4.2. Canada
         9.5. Market Attractiveness Analysis
                9.5.1. By Therapy Type
                9.5.2. By Distribution Channel
                9.5.3. By Country

    10. Europe Pediatric Neuroblastoma Treatment Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
         10.2. Market Value Forecast, by Therapy Type, 2016–2026
                10.2.1. Immunotherapy
                10.2.2. Chemotherapy
                10.2.3. Others
         10.3. Market Value Forecast, by Distribution Channel, 2016–2026
                10.3.1. Hospital Pharmacies
                10.3.2. Retail Pharmacies & Drug Stores
         10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
                10.4.1. Germany
                10.4.2. U.K.
                10.4.3. France
                10.4.4. Rest of Europe
         10.5. Market Attractiveness Analysis
                10.5.1. By Therapy Type
                10.5.2. By Distribution Channel
                10.5.3. By Country/Sub-region

    11. Rest of the World Pediatric Neuroblastoma Treatment Market Analysis and Forecast
         11.1. Introduction
                11.1.1. Key Findings
         11.2. Market Value Forecast, by Therapy Type, 2016–2026
                11.2.1. Immunotherapy
                11.2.2. Chemotherapy
                11.2.3. Others
         11.3. Market Value Forecast, by Distribution Channel, 2016–2026
                11.3.1. Hospital Pharmacies
                11.3.2. Retail Pharmacies & Drug Stores
         11.4. Market Attractiveness Analysis
                11.4.1. By Therapy Type
                11.4.2. By Distribution Channel

    12. Company Profiles
         12.1. United Therapeutics Corporation
                12.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                12.1.2. Product Portfolio
                12.1.3. SWOT Analysis
                12.1.4. Financial Overview
                12.1.5. Strategic Overview
         12.2. APEIRON Biologics AG
                12.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                12.2.2. Product Portfolio
                12.2.3. SWOT Analysis
                12.2.4. Financial Overview
                12.2.5. Strategic Overview
         12.3. Baxter 
                12.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                12.3.2. Product Portfolio
                12.3.3. SWOT Analysis
                12.3.4. Financial Overview
                12.3.5. Strategic Overview
         12.4. Cellectar Biosciences, Inc.
                12.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                12.4.2. Product Portfolio
                12.4.3. SWOT Analysis
                12.4.4. Financial Overview
                12.4.5. Strategic Overview
         12.5. Pfizer, Inc.
                12.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                12.5.2. Product Portfolio
                12.5.3. SWOT Analysis
                12.5.4. Financial Overview
                12.5.5. Strategic Overview
         12.6. MacroGenics, Inc.
                12.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                12.6.2. Product Portfolio
                12.6.3. SWOT Analysis
                12.6.4. Financial Overview
                12.6.5. Strategic Overview
         12.7. Bayer AG
                12.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                12.7.2. Product Portfolio
                12.7.3. SWOT Analysis
                12.7.4. Financial Overview
                12.7.5. Strategic Overview

    List of Tables

    Table 01: List of acronyms used in the report
    Table 02: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 03: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 04: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 05: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 06: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 07: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 08: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 09: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 10: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 11: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 12: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 13: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 14: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
    Table 15: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
    Table 16: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 17: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 18: North America Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 19: North America Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
    Table 20: North America Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 21: Europe Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 22: Europe Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
    Table 23: Europe Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 24: Rest of the World Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
    Table 25: Rest of the World Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

    List of Figures

    Figure 01: Global Pediatric Neuroblastoma Treatment Market
    Figure 02: Global Pediatric Neuroblastoma Treatment Market Size (US$ Mn), by Therapy Type, 2017
    Figure 03: Global Pediatric Neuroblastoma Treatment Market Segments with Leading Market Share (%), 2017
    Figure 04: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, 2016–2026
    Figure 05: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017
    Figure 06: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017
    Figure 07: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Region, 2017
    Figure 08: Key Industry Events
    Figure 09: Porter’s Five Forces Analysis
    Figure 10: Epidemiology of Neuroblastoma 
    Figure 11: Epidemiology of Neuroblastoma: Numbers of Annual New Neuroblastoma Cases in Key Markets
    Figure 12: Epidemiology of Neuroblastoma Key Research Findings
    Figure 13: Epidemiology of Neuroblastoma, by Country
    Figure 14: Epidemiology of Neuroblastoma, by Country
    Figure 15: Epidemiology of Neuroblastoma, by Country
    Figure 16: Key Unmet Needs in the Pediatric Neuroblastoma Treatment Market 
    Figure 17: Global Pediatric Neuroblastoma Treatment Market: Rate of Metastasis to the Brain
    Figure 18: Global Pediatric Neuroblastoma Treatment Market: Rate of Metastasis to the Brain
    Figure 19: Global Pediatric Neuroblastoma Treatment Market: Neuroblastoma Relapse/Refractory cases 
    Figure 20: Global Pediatric Neuroblastoma Treatment Market: Neuroblastoma Relapse/Refractory cases 
    Figure 21: Global Pediatric Neuroblastoma Treatment Market: Utilization of MIBG-131
    Figure 22: Global Pediatric Neuroblastoma Treatment Market: Utilization of MIBG-131
    Figure 23: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
    Figure 24: Global Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
    Figure 25: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Immunotherapy, 2016–2026
    Figure 26: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Chemotherapy, 2016–2026
    Figure 27: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Others, 2016–2026
    Figure 28: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
    Figure 29: Global Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 30: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2016–2026
    Figure 31: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Retail Pharmacies & Drug Stores, 2016–2026
    Figure 32: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Region, 2017 and 2026
    Figure 33: Global Pediatric Neuroblastoma Treatment Market Attractiveness, by Region, 2018–2026
    Figure 34: North America Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) forecast, 2016–2026
    Figure 35: North America Pediatric Neuroblastoma Treatment Market Value Share (%), by Country, 2017 and 2026
    Figure 36: North America Pediatric Neuroblastoma Treatment Market Attractiveness, by Country, 2018–2026
    Figure 37: North America Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
    Figure 38: North America Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
    Figure 39: North America Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
    Figure 40: North America Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 41: Europe Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, 2016–2026
    Figure 42: Europe Pediatric Neuroblastoma Treatment Market Value Share (%), by Country/Sub-region, 2017 and 2026
    Figure 43: Europe Pediatric Neuroblastoma Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
    Figure 44: Europe Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
    Figure 45: Europe Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
    Figure 46: Europe Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
    Figure 47: Europe Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 48: Rest of the World Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 49: Rest of the World Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
    Figure 50: Rest of the World Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
    Figure 51: Rest of the World Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
    Figure 52: Rest of the World Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
    Figure 53: United Therapeutics Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 54: United Therapeutics Corporation Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 55: United Therapeutics Corporation Breakdown of Net Sales, by Product, 2017
    Figure 56: United Therapeutics Corporation Research and Development Cost (US$ Mn), 2015–2017
    Figure 57: United Therapeutics Corporation: SWOT Analysis
    Figure 58: MacroGenics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 59: MacroGenics, Inc. Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 60: MacroGenics, Inc. Net sales (US$ Mn) by key brands
    Figure 61: MacroGenics, Inc. Research and Development Cost (US$ Mn), 2015–2017
    Figure 62: MacroGenics, Inc.: SWOT Analysis
    Figure 63: APEIRON Biologics AG: SWOT Analysis
    Figure 64: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017
    Figure 65: Baxter Breakdown of Net Sales (%), by Region, 2017
    Figure 66: Baxter pipeline of generic products, 2016–2020
    Figure 67: Baxter: SWOT Analysis
    Figure 68: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 69: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
    Figure 70: Pfizer Inc.: SWOT Analysis
    Figure 71: Cellectar Biosciences, Inc. Research and Development Cost (US$ Mn) and Y-o-Y Growth (%), 2016–2017
    Figure 72: Cellectar Biosciences, Inc.: SWOT Analysis
    Figure 73: Bayer Group Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2017
    Figure 74: Bayer Group Breakdown of Net Sales (%), by Region, 2017
    Figure 75: Bayer Group Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 76: Bayer Group: SWOT Analysis

Copyright © Transparency Market Research, Inc. All Rights reserved